Results 91 to 100 of about 21,829 (156)

Experience with ceftazidime–avibactam treatment in a tertiary care center in Saudi Arabia

Journal of Infection and Public Health, 2018
Introduction: Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide.
Abdullah Algwizani, Mohammad Alzunitan, Ahmad Alharbi, Abdulrahman Alsaedy, Sameera Aljohani, Bassam Alalwan, Jawaher Gramish, Adel Alothman   +7 more
doaj   +1 more source

Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa

, 2017
Objectives: When tested in broth, avibactam reverses ceftazidime resistance in many Pseudomonas aeruginosa that express ESBLs. We examined whether similar reversal is observed against intracellular forms of P. aeruginosa.
Krause, K.M., Nichols, W. W., Muccioli, Giulio, Buyck, Julien, Van Bambeke, Françoise, Luyckx, C., Tulkens, Paul M.   +6 more
core   +1 more source

Suboptimal ceftazidime-avibactam exposure drives sequential blaKPC mutations and intra-host coexistence of Klebsiella pneumoniae harboring distinct variants leading to persistent infection

Microbiology Spectrum
KPC-producing Klebsiella pneumoniae infections are a rising global health threat. The factors driving blaKPC mutations during treatment and their contribution to infection persistence remain unclear.
Feng Yang, Weiwei Yang, Jinghao Zhang, Chengkang Tang, Li Ding, Siquan Shen, Yanhao Zhou, Hongyu Zhao, Jiaojiao Zhou, Fupin Hu   +9 more
doaj   +1 more source

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam

Background: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem resistant Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics.
Mithilesh Kumar Jha, Mukesh Kumar, Sunali, Maneesh Kumar, Nishant Ranjan   +4 more
core   +1 more source

Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections

, 2017
Ceftazidime-avibactam is a novel cephalosporin–beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE).
Safia Kuriakose, Madeline King, Kenneth Biason, Jason C. Gallagher, Vanthida Huang, Julianne Gardner, Dorothy McCoy, Nicole Harrington, Lynette Richards, Claudine El-Beyrouty, Emily Heil, Tiffany Bias, Jon Hiles   +12 more
core   +1 more source

**In vitro** antibacterial activity of the ceftazidime-avibactam (NXL104) combination against **Pseudomonas aeruginosa** clinical isolates

, 2012
: The beta-lactamase inhibitor avibactam (NXL104) displays potent inhibition of both class A and C enzymes. The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa ...
Goossens, Herman, Coleman, Kenneth, Girard, Anne-Marie, Claudon, Monique, Black, Michael T., Levasseur, Premavathy, Miossec, Christine   +6 more
core  

In-vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase

, 2015
Ceftazidime-avibactam is active against most Enterobacteriaceae isolates with KPC carbapenemases. We investigated whether this activity could be compromised by mutation.
Warner, Marina, Mustafa, Nazim, Livermore, David, Nichols, Wright W., Jamrozy, Dorota, Woodford, Neil, Mushtaq, Shazad   +6 more
core   +1 more source

The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020

Eurosurveillance
Background Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens.
Berit Muller-Pebody
doaj   +1 more source

Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance

mSystems
Klebsiella pneumoniae carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive.
Jie Wei, Jinyu Huang, Chunhong Zou, Shimei Shen, Barry N. Kreiswirth, Ailong Huang, Shifeng Huang, Liang Chen, Deqiang Wang, Siqiang Niu   +9 more
doaj   +1 more source

Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae

, 2017
We determined imipenem, imipenem-relebactam, ceftazidime, and ceftazidime-avibactam MICs against 100 CRE isolates that underwent whole-genome sequencing.
Palash Samanta, M. Hong Nguyen, Liang Chen, Ghady Haidar, Ryan K. Shields, Barry N. Kreiswirth, Cornelius J. Clancy   +6 more
core   +1 more source